Neoadjuvant hormone therapy with kasodex in a dose 150 mg prior toradical prostatectomy in patients with prostatic cancer


如何引用文章

全文:

详细

参考

  1. Чиссов В. И., Старинский В. В. (ред.) Злокачественные новообразования в России в 2001 г. (заболеваемость и смертность). М.; 2003. 19.
  2. Чиссов В. И., Старинский В. В. (ред.) Состояние онкологической помощи населению России в 2002 г. М., 2003. 28.
  3. Zincke H., Oesterling J. E., Blute M. L. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol. (Baltimore) 1994; 152 (5, pt2): 1850-1857.
  4. Abbas F., Scardino P. T. Why neoadjuvant androgen deprivation prior radical prostatectomy is unnecessary. Urol. Clin. N. Am. 1996; 23: 587.
  5. Wieder J. F., Soloway M. S. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J. Urol. (Baltimore) 1998; 160: 299.
  6. Lerner S. E., Blute M. L., Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J. Urol. (Baltimore) 1995; 154: 1447-1552.
  7. Vallet B. S. Radical perineal prostatectomy subsequent to bilateral orchidectomy. DEL. Med. J. 1944; 16: 18-20.
  8. Scott W. V., Boyd H. L. Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate a retrospective study based upon 25 years of experience. J. Urol. (Baltimore) 1969; 101: 86-92.
  9. Bruchovsky N. The metabolism of testosterone and dihydrotestosterone in androgendependent tumor. A possible correlation between dihydrotestosterone and tumor growth in vivo. Biochem. J. 1972; 127: 561-566.
  10. Isaaks J. Т., Coffey D. S. Adaptation vs selection as the mechanism responsible for relapse of prostate cancer to androgen ablation therapy as studied in the Dunning R-3327H adenocarcinoma. Cancer Res. 1981; 41: 5070-5075.
  11. Labrie F., Dupont F., Cusan L. et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and Lupron: the first controlled and randomized trial. Clin. Invest. Med. 1993; 16: 499-509.
  12. Soloway M. S., Sharifi R., Wajsman Z. et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMx) prostate cancer. J. Urol. (Baltimore) 1995; 154: 424-428.
  13. Amling С. L., Blute M. L., Bergstralh E. J. et al. Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer. Semin. Urol. Oncol. 1997; 15: 222-229.
  14. Aus G., Abrahamsson P., Ahgren G. et al. Hormonal treatment before radical prostatectomy: a 3-year follow-up. J. Urol. (Baltimore) 1998; 159: 2013-2017.
  15. Witjes W. P., Schulman С. С., Debruyne F. M. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3N0M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 1997; 49 (ЗА, suppl.): 65-69.
  16. See W., Iversen P., Wirth M. et al. Immediate treament with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. Eur. Urol. 2003; 44 (5): 512-517.
  17. Iversen P., Tyrrell С. J., Kaisary A. V. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J. Urol. (Baltimore) 2000; 164 (5): 1579-1582.
  18. Tyrrell С. J., Kaisary A. V., Iversen P. et al. A randomised comparison of'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur. Urol. 1998; 33 (5): 447-456.
  19. Goldenberg S. L., Klotz L. H., Srigley J. et al. Randomized, prospective controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J. Urol. (Baltimore) 1996; 156: 873- 877.
  20. Klotz L. K., Goldenberg S. L., Jewett M. et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. Urology 1999; 53 (4): 757-763.
  21. Van Poppel H., De Kidder D., Elgamal A. A. et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J. Urol. (Baltimore) 1995; 154 (2, pt 1): 429-434.
  22. Dalkin B. L., Ahmann F. R., Nagle R. et al. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J. Urol. (Baltimore) 1996; 155 (4): 1357-1360.
  23. Русаков И. Т., Алексеев Б. Я., Воробьев Н. В. и др. Неоадъювантная и адъювантная терапия при лечении локализованного и местно-распространенного рака предстательной железы. В кн.: Актуальные вопросы лечения онкоурологических заболеваний: (Материалы V Всероссийской науч.- практ. конф. с международным участием - Обнинск, 2- 3 окт. 2003 г.) Обнинск; 2003. 135-137.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2004
##common.cookie##